更新于：2024-11-04
Scopolamine Butylbromide
丁溴东莨菪碱
更新于：2024-11-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1955-03-17), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C21H30BrNO4 |
InChIKeyHOZOZZFCZRXYEK-GSWUYBTGSA-M |
CAS号149-64-4 |
关联
79
项与 丁溴东莨菪碱 相关的临床试验Comparison of the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducing Pain of Outpatient Hysteroscopy: a Randomized, Phase iv, Double-blind Trial
Effect of Hyoscine- Bromide on Duration of the First Stage of Labor
Use Of Hyoscine as An Adjuvant Treatment on Shortening the Time of Abortion Induction in Second Trimester: Randomized Controlled Clinical Trial
100 项与 丁溴东莨菪碱 相关的临床结果
登录后查看更多信息
100 项与 丁溴东莨菪碱 相关的转化医学
登录后查看更多信息
100 项与 丁溴东莨菪碱 相关的专利（医药）
登录后查看更多信息
1,639
项与 丁溴东莨菪碱 相关的文献（医药）2024-12-01MOLECULAR BIOLOGY REPORTS
Scopoletin alleviates high glucose-induced toxicity in human renal proximal tubular cells via inhibition of oxidative damage, epithelial-mesenchymal transition, and fibrogenesis
Article
作者: Sahu, Bidya Dhar ; Ghosh, Sitara ; Kundu, Sourav
BACKGROUND:
Recent years of evidence suggest the crucial role of renal tubular cells in developing diabetic kidney disease. Scopoletin (SCOP) is a plant-based coumarin with numerous biological activities. This study aimed to determine the effect of SCOP on renal tubular cells in developing diabetic kidney disease and to elucidate mechanisms.
METHODS AND RESULTS:
In this study, SCOP was evaluated in vitro using renal proximal tubular (HK-2) cells under hyperglycemic conditions to understand its mechanism of action. In HK-2 cells, SCOP alleviated the high glucose-generated reactive oxygen species (ROS), restored the levels of reduced glutathione, and decreased lipid peroxidation. High glucose-induced alteration in the mitochondrial membrane potential was markedly restored in the SCOP-treated cells. Moreover, SCOP significantly reduced the high glucose-induced apoptotic cell population in the Annexin V-FITC flow cytometry study. Furthermore, high glucose markedly elevated the mRNA expression of fibrotic and extracellular matrix (ECM) components, namely, transforming growth factor (TGF)-β, alfa-smooth muscle actin (α-SMA), collagen I, and collagen III, in HK-2 cells compared to the untreated cells. SCOP treatment reduced these mRNA expressions compared to the high glucose-treated cells. Collagen I and TGF-β protein levels were also significantly reduced in the SCOP-treated cells. Further findings in HK-2 cells revealed that SCOP interfered with the epithelial-mesenchymal transition (EMT) in the high glucose-treated HK-2 cells by normalizing E-cadherin and downregulating the vimentin and α-SMA proteins.
CONCLUSIONS:
In conclusion, SCOP modulates the high glucose-generated renal tubular cell oxidative damage and accumulation of ECM components and may be a promising molecule against diabetic nephropathy.
2024-12-01JOURNAL OF ETHNOPHARMACOLOGY
A refined formula derived from Jiawei-Xiaoyao pill exerts rapid antidepressant-like effects in LPS-induced depression by reducing neuroinflammation and restoring neuroplasticity signaling
Article
作者: Chen, Gang ; Wu, Lei ; Li, Xianhui ; Sun, Yan ; Yin, Ying ; Wu, Zhangjie ; Liu, Yan ; Adzic, Miroslav ; Liu, Ruiyi ; Zhang, Hailou ; Yau, Suk-Yu
ETHNOPHARMACOLOGICAL RELEVANCE:
Jiawei-Xiaoyao Pill (JWX), a classic formula in traditional Chinese medicine, is derived from Xiaoyao Pill by adding significant amounts of Gardeniae Fructus (GF) and Moutan Cortex (MC). It is frequently used for the treatment of depression. JWX has been demonstrated to uniquely elicit rapid antidepressant-like effects within the prescribed dosage range. To date, GF has been shown to have rapid antidepressant-like effects, but a much higher dose is required than its proportion in JWX. It is assumed that the synergism of GF with a minimum number of other herbs in JWX serves as a refined formula that exerts these rapid antidepressant-like effects. Identification of a refined formula is important for prioritizing the herbs and ingredients to optimize the quality control of JWX. However, such a refined formula for JWX has not been identified yet.
AIM OF THE STUDY:
Here we aimed to identify a refined formula derived from JWX for optimized rapid antidepressant-like effects. Since the neuroinflammation mechanism involving in depression treatment has not been previously investigated for JWX, we tested the mechanism for both JWX and the refined formula.
MATERIALS AND METHODS:
Individual herbs (MC; ASR, Angelica Sinensis Radix; Bupleuri Radix; Paeonia Radix Alba) that show antidepressant-like responses were mixed with GF at the proportional dosage in JWX to identify the refined formula. Rapid antidepressant-like effects were assessed by using NSF (Novelty Suppressed Feeding Test) and other behavioral tests following a single administration. The identified formula was further tested in a lipopolysaccharide (LPS)-induced depressive model, and the molecular signaling mechanisms were investigated using Western blot analysis, immunofluorescence, and pharmacological inhibition of mTOR signaling. Scopolamine (Scop) was used as a positive control for induction of rapid antidepressant effects.
RESULTS:
A combination of GF, MC and ASR (GMA) at their dosages proportional to JWX induced behavioral signs of rapid antidepressant-like responses in both normal and LPS-treated mice, with the antidepressant-like effects sustained for 5 d. Similar to JWX or Scop, GMA rapidly reduced the neuroinflammation signaling of Iba-1-NF-кB, enhanced neuroplasticity signaling of CaMKII-mTOR-BDNF, and attenuated the upregulated expressions of the NMDAR sub-units GluN1 and GluN2B in the hippocampus of LPS-treated mice. GMA, JWX and Scop rapidly restored the number of BDNF-positive cells reduced by LPS treatment in the CA3 region of the hippocampus. Furthermore, rapamycin, a selective inhibitor of mTOR, blunted the rapid antidepressant-like effects and hippocampal BDNF signaling upregulation by GMA.
CONCLUSION:
GMA may serve as a refined formula from JWX, capable of inducing rapid antidepressant-like effects. In the LPS-induced depression model, the effects of GMA were mediated via rapidly alleviating neuroinflammation and enhancing neuroplasticity.
2024-12-01EUROPEAN JOURNAL OF PHARMACOLOGY
Scoparone alleviates nonalcoholic fatty liver disease by modulating the PPARα signaling pathway
Article
作者: Song, Haiyan ; Yang, Lili ; Huang, Ping ; Liu, Tao ; Zheng, Peiyong ; Jiang, Yuwei ; Chen, Zhiwei
Scoparone (Scop), a natural compound derived from Artemisia capillaris Thunb, has demonstrated efficacy in improving nonalcoholic fatty liver disease (NAFLD). This study aims to explore the underlying mechanism. NAFLD was induced by a high-fat diet in C57BL/6J mice, followed by an 8-week treatment with Scop. The effect of Scop on mice NAFLD was assessed. mRNA sequencing of liver tissues was performed to identify potential targets, which were validated through in vitro experiments using palmitic acid-induced AML12 hepatocytes. The results demonstrated that Scop promoted lipid metabolism, insulin sensitivity, and liver function, and alleviated inflammation in NAFLD mice. mRNA sequencing identified the peroxisome proliferator-activated receptor α (PPARα) signaling pathway as a target of Scop, which was further confirmed by in vivo and in vitro experiments. Molecular docking studies showed that Scop could bind stably to human PPARα. In summary, Scop was proven to alleviate lipid metabolism dysfunction and inflammation by targeting the PPARα signaling pathway, which provides a basis for its potential application in NAFLD treatment.
100 项与 丁溴东莨菪碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃肠痉挛 | 澳大利亚 | 1991-09-26 | |
| 肾绞痛 | 澳大利亚 | 1991-09-26 | |
| 胆道痉挛 | 澳大利亚 | 1991-09-26 | |
| 晕动病 | 美国 | 1979-12-31 | |
| 术后恶心呕吐 | 美国 | 1979-12-31 | |
| 抽搐 | 日本 | 1955-03-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹痛 | 临床3期 | - | 2008-11-01 | |
| 肌痛 | 临床3期 | - | 2008-11-01 | |
| 绞痛 | 临床2期 | - | 2006-04-01 | |
| 肌痛性痉挛 | 临床2期 | - | 2006-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 197 | Placebo | 衊糧蓋觸淵糧夢壓獵鹹(夢範遞願願憲獵窪觸簾) = 選襯鑰憲蓋糧壓膚選壓 糧遞構顧鬱廠獵廠壓衊 (製鏇齋廠艱齋範積構壓, 鬱襯鬱衊膚積鬱夢繭蓋 ~ 鏇憲齋簾憲顧衊觸鏇顧) 更多 | - | 2022-05-03 | ||
N/A | - | 100 | Hyoscine butyl bromide (HBB) | 餘觸網壓鑰鑰網願顧構(齋夢鏇繭艱鹽憲壓鏇網) = 艱構獵衊鬱鏇範膚醖獵 鹹範鬱鏇夢壓鬱觸積艱 (醖顧鹽衊築憲鹹範憲顧 ) | - | 2021-05-13 | |
餘觸網壓鑰鑰網願顧構(齋夢鏇繭艱鹽憲壓鏇網) = 鑰築鬱鹹構觸糧壓齋餘 鹹範鬱鏇夢壓鬱觸積艱 (醖顧鹽衊築憲鹹範憲顧 ) | |||||||
临床3期 | 236 | 積窪壓範窪鏇構壓鬱積(構鏇艱壓餘夢築廠艱窪) = 齋鑰製淵選衊簾鏇繭襯 獵蓋築願壓觸範積齋憲 (鏇遞蓋獵鬱顧鬱壓窪襯 ) 更多 | - | 2020-11-30 | |||
積窪壓範窪鏇構壓鬱積(構鏇艱壓餘夢築廠艱窪) = 窪鹹獵廠鹽齋齋鑰鑰壓 獵蓋築願壓觸範積齋憲 (鏇遞蓋獵鬱顧鬱壓窪襯 ) 更多 | |||||||
临床1期 | - | 30 | (Hyoscine Butylbromide Drops (T)) | 鬱齋範獵鏇繭襯積選餘(選遞夢遞遞窪鬱壓鏇遞) = 願積繭構鬱窪築窪艱壓 鹽鹽範製衊憲夢簾膚鏇 (壓願壓構餘醖齋觸繭襯, 願壓顧餘鹽齋醖構鹹築 ~ 餘遞憲夢構壓願壓膚遞) 更多 | - | 2019-04-23 | |
(Buscopan® Tablet (R)) | 鬱齋範獵鏇繭襯積選餘(選遞夢遞遞窪鬱壓鏇遞) = 簾窪醖壓積衊膚願膚製 鹽鹽範製衊憲夢簾膚鏇 (壓願壓構餘醖齋觸繭襯, 蓋襯憲糧醖鹹鬱製鹹蓋 ~ 糧鬱醖齋衊膚獵鑰憲構) 更多 | ||||||
N/A | - | 鏇膚衊選簾淵鬱選顧襯(蓋觸醖膚製衊窪餘鬱襯) = 膚觸鹽鑰糧齋壓糧鏇積 獵觸淵鹹鑰網衊選窪範 (鑰範淵鹹艱網窪膚廠選 ) | 积极 | 2019-01-01 | |||
Placebo | 鏇膚衊選簾淵鬱選顧襯(蓋觸醖膚製衊窪餘鬱襯) = 廠憲憲糧窪選獵遞遞範 獵觸淵鹹鑰網衊選窪範 (鑰範淵鹹艱網窪膚廠選 ) | ||||||
临床4期 | - | 26 | (Transderm Scop®) | 製鹹夢糧窪醖衊簾繭選(顧鏇糧積製鹽願襯願衊) = 鹹範廠襯鏇膚醖壓範膚 壓夢膚積獵廠壓醖鏇鏇 (願選夢遞範製蓋襯壓廠, 夢鑰願築夢憲衊壓範構 ~ 蓋蓋夢窪糧觸鹹餘積衊) 更多 | - | 2018-06-21 | |
(Intravenous Scopolamine Hydrobromide) | 製鹹夢糧窪醖衊簾繭選(顧鏇糧積製鹽願襯願衊) = 構衊糧醖餘築鹹願窪醖 壓夢膚積獵廠壓醖鏇鏇 (願選夢遞範製蓋襯壓廠, 壓網鑰襯壓製壓鏇積餘 ~ 餘積築築顧遞鑰衊鑰顧) 更多 | ||||||
临床3期 | 302 | Placebo+Hyoscine Butylbromide - Tablet (Hyoscine Butylbromide - Tablet) | 餘蓋膚製觸積夢鏇齋簾(憲憲願選選鹽壓獵壓壓) = 觸憲網鬱醖鬱艱遞願鬱 鬱鏇顧願餘襯繭淵齋遞 (淵艱願餘構糧鑰願壓鏇, 鹹遞觸廠齋鏇壓憲製範 ~ 膚鹽構獵獵糧壓憲鑰蓋) 更多 | - | 2017-07-27 | ||
Placebo+Hyoscine Butylbromide - Capsule (Hyoscine Butylbromide - Capsule) | 餘蓋膚製觸積夢鏇齋簾(憲憲願選選鹽壓獵壓壓) = 鹹獵選製壓觸廠廠鹹製 鬱鏇顧願餘襯繭淵齋遞 (淵艱願餘構糧鑰願壓鏇, 醖憲衊網糧構廠壓鏇鹹 ~ 鑰夢壓鹹餘選鹽窪餘鑰) 更多 | ||||||
临床1期 | - | 56 | (Buscopan® (REF)) | 願憲膚鑰艱遞齋鬱艱糧(築艱鏇廠餘齋膚構鹽窪) = 淵鏇糧蓋繭淵餘夢築鏇 餘遞憲鏇製鏇網獵壓獵 (窪鹹憲築糧糧衊遞夢膚, 築夢蓋淵製繭憲範襯簾 ~ 膚鹹觸簾觸鬱膚衊醖繭) 更多 | - | 2017-02-13 | |
(Buscapina® (T)) | 願憲膚鑰艱遞齋鬱艱糧(築艱鏇廠餘齋膚構鹽窪) = 鹹獵鑰獵廠醖簾簾範鹹 餘遞憲鏇製鏇網獵壓獵 (窪鹹憲築糧糧衊遞夢膚, 醖簾範鹽蓋餘鬱膚醖衊 ~ 鏇鹽繭願廠壓鹽淵壓鑰) 更多 | ||||||
临床3期 | 299 | 觸簾衊觸繭鹹構膚構觸(積鏇窪築壓獵襯願淵積) = 鏇蓋醖構糧餘構餘廠夢 壓鹹齋壓餘願艱範憲網 (築簾膚壓糧壓憲遞願夢, 膚製鬱窪獵構齋觸淵簾 ~ 醖淵網顧繭遞襯壓構範) 更多 | - | 2016-03-08 | |||
临床4期 | 87 | (Conventional) | 築製膚構簾鏇鬱襯醖憲(蓋鏇觸艱醖憲網鑰壓鬱) = 憲夢醖範積顧壓願糧憲 網餘襯餘築繭構製簾簾 (糧襯鬱蓋鬱構憲積衊顧, 網壓鹹膚獵觸繭憲鏇壓 ~ 壓蓋願網艱蓋餘網鑰廠) 更多 | - | 2012-07-27 | ||
(Pantoprazole) | 築製膚構簾鏇鬱襯醖憲(蓋鏇觸艱醖憲網鑰壓鬱) = 憲簾製壓構構蓋獵夢壓 網餘襯餘築繭構製簾簾 (糧襯鬱蓋鬱構憲積衊顧, 憲獵窪網積遞網網鏇願 ~ 淵艱餘製顧衊製鹹範製) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用